News
The NHS has provided health and care, free at the point of delivery, for more than 75 years. It is rightly held as a national ...
Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...
Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because ...
Comparator companies Ipsen (somatropin) (confidentiality agreement not signed, not participating) Lilly (somatropin) (confidentiality agreement not signed, not participating) Merck Serono (somatropin) ...
Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care Clinical guideline Reference number: ...
The meeting will take place via Zoom, a secure web conferencing tool. You will need to join the meeting by 10:00am and it is expected to finish at approximately 3:00pm, although this may be subject to ...
It is essential to provide reliable evidenced-based information on the benefits and risks of HRT to aid shared decision making between women, trans men and non-binary people registered female at birth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results